Skip to main content

Table 2 Surgical and postoperative pathological characteristics, and treatment of the SGC and MGC of the entire cohort (n = 4107) and after propensity score matching (n = 665)

From: Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers: a propensity score matching analysis

Parameters

Entire cohort (before matching)

P value

Propensity score matched cohort

P value

SGC, n (%)

MGC, n (%)

SGC, n (%)

MGC, n (%)

Surgical approach

  

0.414

  

0.959

 Open

802 (20.2)

23 (17.3)

 

93 (17.5)

23 (17.3)

 

 Laparoscopic

3172 (79.8)

110 (82.7)

 

439 (82.5)

110 (82.7)

 

Type of gastrectomy

  

< 0.001

  

1.000

 Total

2129 (53.6)

106 (79.7)

 

424 (79.7)

106 (79.7)

 

 Distal

1782 (44.8)

27 (20.3)

 

108 (20.3)

27 (20.3)

 

 Proximal

63 (1.6)

0 (0.0)

 

0 (0.0)

0 (0.0)

 

Number of eLNs

  

0.547

  

0.514

 ≤ 15

161 (4.1)

4 (3.0)

 

11 (2.1)

4 (3.0)

 

 > 15

3813 (95.9)

129 (97.0)

 

521 (97.9)

129 (97.0)

 

pT stage

  

0.033

  

0.706

 T1

983 (24.7)

20 (15.0)

 

98 (18.4)

20 (15.0)

 

 T2

446 (11.2)

17 (12.8)

 

54 (10.2)

17 (12.8)

 

 T3

1165 (29.3)

37 (27.8)

 

144 (27.1)

37 (27.8)

 

 T4a

1380 (34.7)

59 (44.4)

 

236 (44.4)

59 (44.4)

 

pN stage

  

0.035

  

0.909

 N0

1442 (36.3)

37 (27.8)

 

157 (29.5)

37 (27.8)

 

 N1

601 (15.1)

16 (12.0)

 

73 (13.7)

16 (12.0)

 

 N2

680 (17.1)

23 (17.3)

 

86 (16.2)

23 (17.3)

 

 N3

1251 (31.5)

57 (42.9)

 

216 (40.6)

57 (42.9)

 

pTNM stage

  

0.041

  

0.430

 Stage I

1143 (28.8)

25 (18.8)

 

123 (23.1)

25 (18.8)

 

 Stage II

875 (22.0)

32 (24.1)

 

107 (20.1)

32 (24.1)

 

 Stage III

1956 (49.2)

76 (57.1)

 

302 (56.8)

76 (57.1)

 

Tumor size

  

0.222

  

0.843

 ≤ 5 cm

2652 (66.7)

82 (61.7)

 

323 (60.7)

82 (61.7)

 

 > 5 cm

1322 (33.3)

51 (38.3)

 

209 (39.3)

51 (38.3)

 

Tumor histological type

  

0.640

  

0.860

 Differentiated

1150 (28.9)

36 (27.1)

 

140 (26.3)

36 (27.1)

 

 Undifferentiated

2824 (71.1)

97 (72.9)

 

392 (73.7)

97 (72.9)

 

Postoperative complications

  

0.242

  

0.481

 Absent

3182 (80.1)

101 (75.9)

 

419 (78.8)

101 (75.9)

 

 Present

792 (19.9)

32 (24.1)

 

113 (21.2)

32 (24.1)

 

Adjuvant chemotherapya

  

0.069

  

0.852

 No

1263 (42.2)

38 (33.6)

 

150 (34.6)

38 (33.6)

 

 Yes

1728 (57.8)

75 (66.4)

 

284 (65.4)

75 (66.4)

 
  1. SGC solitary gastric cancers, MGC multiple gastric cancers, eLNs examined lymph nodes, pT stage pathological tumor stage, pN stage pathological node stage, pTNM stage pathological tumor-node-metastasis stage
  2. aAdjuvant chemotherapy only patients with advanced gastric cancer were analyzed, which included 3104 patients before matching and 547 after matching